Pyxis Oncology, Inc.
NASDAQ:PYXS
1.51 (USD) • At close February 5, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Pyxis Oncology, Inc. |
Symbool | PYXS |
Munteenheid | USD |
Prijs | 1.51 |
Beurswaarde | 89,793,252 |
Dividendpercentage | 0% |
52-weken bereik | 1.39 - 6.85 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Lara S. Sullivan M.D., MBA |
Website | https://www.pyxisoncology.com |
An error occurred while fetching data.
Over Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC),
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)